Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 13
Submit an article Journal homepage
389
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Brian J. BallDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8625-7023View further author information
ORCID Icon,
Shukaib ArslanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Paul KollerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Dat NgoDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Michelle AfkhamiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Amandeep SalhotraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0002-9302-5041View further author information
ORCID Icon,
Monzr Al-MalkiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0001-8226-471XView further author information
ORCID Icon,
Ahmed AribiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Haris AliDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Karamjeet SandhuDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Salman OtoukeshDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Idoroenyi AmanamDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0003-4819-4628View further author information
ORCID Icon,
Hoda PourhassanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0003-3862-4612View further author information
ORCID Icon,
Andrew ArtzDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0003-0803-9607View further author information
ORCID Icon,
Peter CurtinDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Anthony SteinDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Ryotaro NakamuraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0002-9082-0680View further author information
ORCID Icon,
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0002-3983-5908View further author information
ORCID Icon,
Eileen SmithDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Vinod PullarkatDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0001-9129-3424View further author information
ORCID Icon &
Ibrahim AldossDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAORCID Iconhttps://orcid.org/0000-0001-9564-4498View further author information
ORCID Icon show all
Pages 3232-3236 | Received 09 May 2022, Accepted 17 Aug 2022, Published online: 10 Sep 2022

References

  • Bill M, Mrózek K, Kohlschmidt J, et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proc Natl Acad Sci USA. 2020;117(42):26340–26346.
  • Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823–833.
  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Byrd JC, Mrózek K, Dodge RK, Cancer and Leukemia Group B (CALGB 8461), et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood. 2002;100(13):4325–4336.
  • Mrózek K, Heinonen K, Lawrence D, et al. Adult patients with De novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood. 1997;90(11):4532–4538.
  • Krauter J, Wagner K, Schäfer I, et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based Meta-analysis of the german acute myeloid leukemia intergroup. J Clin Oncol. 2009;27(18):3000–3006.
  • Chen S-J, Shen Y, Chen Z. A panoramic view of acute myeloid leukemia. Nat Genet. 2013;45(6):586–587.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–629.
  • Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5(5):1552–1564.
  • DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791–803.
  • Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022;6(3):828–847.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.